15th week of 2010 patent applcation highlights part 37 |
Patent application number | Title | Published |
20100092397 | Method For Treatment of COPD and Other Pulmonary Diseases - A method for treatment of patients with pulmonary diseases by providing an aerosolized combination of a methylxanthine and a topical steroid administered into a patient's conducting and central airways. The method utilizes a specific treatment protocol and a nebulizing system providing an aerosol having particles of a predetermined mass medial aerodynamic diameter (MMAD) delivered to the conducting and central lungs with overpressure and under controlled conditions. | 2010-04-15 |
20100092398 | ANTIMICROBIAL COMPOSITIONS AND APPLICATIONS THEREFORE - A composition derived from an essential oil obtained from one or more plants of the | 2010-04-15 |
20100092399 | METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION - Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. | 2010-04-15 |
20100092400 | Salicylic Acid Composition - Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough to support aerosol delivery, and the salicylic acid composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery system, a propellant, wherein the salicylic acid composition is non-irritating and has a non-watery feel. | 2010-04-15 |
20100092401 | IMMUNE RESPONSE MODIFIER FORMULATIONS - The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod and a fatty acid. | 2010-04-15 |
20100092402 | TREATMENT OF RESPIRATORY DISEASE - The invention relates to the use of amidino compounds in the manufacture and formulation of medicaments for the treatment of respiratory diseases. | 2010-04-15 |
20100092403 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLPIDEM - Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant. | 2010-04-15 |
20100092404 | HYDROGENATION OF CARYOPHELLENE - A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin. | 2010-04-15 |
20100092405 | POLYAMINO ACID DERIVATIVES AND USE THEREOF IN COMPOSITIONS FOR TREATING KERATIN FIBERS | 2010-04-15 |
20100092406 | Systems, Methods, and Compositions for Treatment and Use of a Palatal Patch - Devices and methods for a palatal patch include a tablet or strip having a bioadhesive component and an active component. The bioadhesive component allows for the palatal patch to be attached to an upper palate, and for the active component to be released into the oral cavity and/or GI tract. Compositions for the active component include compositions for treatment of halitosis, anti-acids, vitamins, anti-smoking agents, and others. A composition for treatment of halitosis includes at least one of Echinacea, Lavender, Mastic Gum and Sage. A device for delivery of the palatal patch to the upper palate includes a housing and a piston, the piston having a holder for the palatal patch, and wherein the piston may be configured to move distally so as to delivery the palatal patch to the upper palate. | 2010-04-15 |
20100092407 | TOOTH-BLEACHING MATERIAL AND METHOD OF BLEACHING TOOTH - A tooth bleaching material that is safe and has good operability and high bleaching effect and a tooth bleaching method using the tooth bleaching material are provided by bleaching and removing colored sediments (colored or discolored deposits) on a tooth with a tooth bleaching material containing hydrogen peroxide and/or a compound generating hydrogen peroxide in an aqueous solution, and a dicarboxylic anhydride, and also containing a basic compound and a thickening agent, and a tooth bleaching method containing attaching the tooth bleaching material to a surface of a discolored tooth after dilution or without dilution irradiating with light. | 2010-04-15 |
20100092408 | RESILIENT PERSONAL CARE COMPOSITION COMPRISING POLYALKYL ETHER CONTAINING SILOXANE ELASTOMERS - A stable personal care composition in the form of a water-in-oil emulsion may comprise a silicone elastomer comprising a polyalkyl ether pendant or a polyalkyl ether crosslink, wherein the alkyl group contains three or more carbon atoms; a non-emulsifying silicone elastomer; an emulsifier; a polar oil; and water. The personal care composition allows for previously unattainable levels of polar oils and/or aqueous phase within a water-in-oil emulsion. | 2010-04-15 |
20100092409 | PERSONAL CARE COMPOSITIONS COMPRISING MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS - The present invention relates to compositions that comprise modified variant Bowman Birk Protease Inhibitor proteins (BBPIs). The modified variant BBPIs comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses the compositions comprising the modified variant BBPIs, and the methods for making and using the compositions in personal care. | 2010-04-15 |
20100092410 | SPF Liquid Cleansing Compositions - The present application relates to a facial and/or body wash composition that after rinsing provides a sun protection factor of at least about 6 comprising (i) red petrolatum; (ii) at least one surface-treated metal oxide pigment that blocks ultraviolet radiation in the wavelength range of from about 290 nm to about 400 nm; (iii) at least one organic sunscreen agent having a log P of greater than about 4.0 that blocks or absorbs ultraviolet radiation in the wavelength range of from about 290 nm to about 400 nm; (iv) at least one lathering anionic surfactant; (v) at least one lathering non-ionic surfactant; (vi) an alkyl silicone; and (vii) a volatile cyclic silicone. | 2010-04-15 |
20100092411 | HYDROPHOBIC ZINC OXIDE POWDER - Hydrophobic zinc oxide powder in the form of partially or completely coated aggregates of zinc oxide primary particles having a carbon content of from 0.4 to 1.5% by weight, based on the hydrophobic zinc oxide powder, and a BET surface area of from 25 to 100 m | 2010-04-15 |
20100092412 | SELF TANNING COMPOSITIONS CONTAINING DIHYDROXYACETONE, A RETINOID AND ASCORBIC ACID GLUCOSIDE AS A STABILIZER - The invention concerns a composition comprising dihydroxyacetone, a retinoid and a glycosylated ascorbic acid. | 2010-04-15 |
20100092413 | Compositions and Methods for Alleviating Skin Disorders - The disclosure relates to the discovery that fractionated coconut oil is effective for alleviating existing skin disorders when applied topically to the skin of a person afflicted with such a disorder. The disclosure further relates to the discovery that fractionated coconut oil can be used to prevent or inhibit onset of a skin disorder or to reduce the severity of a skin disorder when administered prophylactically to the skin of a person. A cromolyn compound, a corticosteroid, or both, can be included in the composition. | 2010-04-15 |
20100092414 | Guar Protein Extracts and Compositions Comprised Thereof as Surface Treating and/or Modifying Agents - Surface treating and/or modifying compositions, for example cosmetic or pharmaceutical or plant protective compositions or domestic care compositions contain a guar protein extract, or derivative thereof, such guar protein extract containing at least 65% by weight of proteins and are particularly suitable as surface treating and/or modifying agents, wherein these surfaces are, for example, the skin, hairs, domestic care and textile surfaces and plant leaf surfaces. | 2010-04-15 |
20100092415 | HAIR FRIZZINESS REDUCING AGENT - Provided is a hair frizziness reducing agent containing a lower alcohol and water, having a viscosity of from 1 to 90,000 mPa·s and used by leaving, after application to the scalp, the agent as is without washing it away. | 2010-04-15 |
20100092416 | METHOD FOR THE COSMETIC TREATMENT OF KERATIN MATERIALS - The present invention relates to a cosmetic treatment method for keratin materials, especially the hair, comprising the application of a cosmetic composition which comprises a polymer having a polymer backbone comprising amino acid monomer units with cationic function, and comprising hydrophilic grafts bonded covalently to said backbone, over all or part of said backbone, said hydrophilic grafts comprising the repetition of at least two hydrophilic monomer units of formula —CH | 2010-04-15 |
20100092417 | MASCARA COMPOSITION COMPRISING AN ETHYLENE/VINYL ACETATE COPOLYMER - The present invention relates to a mascara composition including a cosmetically acceptable aqueous medium, characterized in that it includes an oily phase including at least one ethylene/vinyl acetate copolymer, and at least one wax or a mixture of waxes in a certain weight ratio. The present invention also relates to a process for the care or make-up of eyelashes or eyebrows, characterized by the fact that a composition according to the invention is applied to the eyelashes or eyebrows. It also relates to the use of a composition according to the invention in order to obtain a make-up for filling and/or curling the eyelashes and/or a smooth and uniform deposition on the eyelashes. | 2010-04-15 |
20100092418 | ISOMERS OF BICYCLO[2.2.1]HEPT-5-ENE-2-CARBOXYLIC ACID, ETHYL ESTER AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to a fragrance compound of bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester: | 2010-04-15 |
20100092419 | MAGNETIC FLUIDS AND THEIR USE - Disclosed are magnetic fluids containing ionic liquids and containing no stabilisation agents or containing selected stabilisation agents. These magnetic fluids can be used in different fields of industry, for example as an ink, as a damping fluid, as a sealing fluid, in imaging applications, in sink flotation techniques, in biomedical applications, as a reaction medium to perform chemical reactions, as a reversible seal for occluding blood vessels in living organisms in medical therapy or as a transportation means and/or delivery means for chemical substances at a selected location within a chemical or biological system. | 2010-04-15 |
20100092420 | Preservative Systems Comprising Cationic Surfactants - Preservative systems on the basis of cationic surfactants are known i n the art, a typical example of such cationic surfactants is the ethyl ester of the lauramide of arginine monohydrochloride (LAE) (2). Besides the chloride form the corresponding bromide and sulphate salts are known. It was found that other salts of the cationic surfactants display excellent properties, such as the salts of lactic acid, glutamic acid and acetic acid. It was further found that the combination of the cationic surfactants with at least one salt of an organic or inorganic acid displayed an excellent preservative action. A further preservative system with favourable properties was the combination of the cationic surfactants with at least one ester compound, amide or enzyme inhibitor. Also the combination of the cationic surfactant with a further cationic molecule such as ethyl arginate, glucosamine or chitosan led to an effective preservative system. A further effective preservative system turned out to be the cationic surfactant in encapsulated form. | 2010-04-15 |
20100092421 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof - Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation. | 2010-04-15 |
20100092422 | Poly ( -hydroxy short-medium chain fatty acid) - The present invention provides a composition comprising a polymer of a β-hydroxy short-medium chain fatty acid, which is used for delivering the β-hydroxy short-medium chain fatty acid or an oligomer thereof to the large intestine. In case the composition is administrated orally, the composition will be delivered to the large intestine, without being degraded in the stomach or short intestine, and degraded by the large intestinal bacterial flora and release the short-medium chain fatty acid or an oligomer thereof. The released short-medium chain fatty acid or an oligomer thereof has useful physiological activities and is effective for treating or preventing inflammatory diseases or cancer in the large intestine. | 2010-04-15 |
20100092423 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis. | 2010-04-15 |
20100092424 | Method of diagnosis and treatment of tumors using high intensity focused ultrasound - A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response. | 2010-04-15 |
20100092425 | Nicotine Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. For example, the present invention nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies. | 2010-04-15 |
20100092426 | 2-SUBSTITUTED BENZIMIDAZOLES - Inhibitors of RSV replication of formula (I) the addition salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydro-thiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; which heterocyle may be substituted with 1-2 substituents; each Alk is C1-6alkanediyl; R1 is Ar2 or optionally substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl or 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; R3 is hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, cyanoC1-6alkyl, aminocarbonyl-C1-6-alkyl, mono- or di(C1-6alkyl)aminocarbonyl-C1-6-alkyl, carboxyl-C1-6-alkyl, C1-6alkoxycarbonyl-C1-6alkyl; R2 is hydrogen or C1-6alkyl; R3 and R4 are hydrogen, C1-6alkyl, Ar2, Ar2C1-6alkyl, C1-6alkylcarbonyl, Ar2carbonyl, Ar2C1-6alkylcarbonyl, C1-6alkylsulfonyl, aminosulfonyl, Ar1sulfonyl, Ar1C1-6alkylsulfonyl, C1-6alkyloxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, hydroxyC1-6alkyl, aminocarbonylC1-6alkyl, C1-4alkyloxycarbonyl-C1-6alkyl, hydroxycarbonylC1-6alkyl, aminosulfonylC1-6alkyl, Het, Het-C1-6alkyl, Het-carbonyl, Het-sulfonyl, HetC1-6alkylsulfonyl, Het-C1-6alkylcarbonyl; Het is an optionally substituted heterocycle; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). | 2010-04-15 |
20100092427 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy - A new class of diketo acids constructed on pyridinone scaffolds, designed as inhibitors of HTV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described. Compounds of the present application include those of formula I and include tautomers, regioisomers, geometric isomers, and pharmaceutically acceptable salts thereof, wherein the pyridinone scaffold and R groups are as otherwise defined in the specification. These are combined, with any number of typical other anti-HIV agents (including other integrase-based anti-HIV agents) and other combination therapeutic agents described herein, to provide an effective treatment modality for HIV infections, including AIDS and ARC. | 2010-04-15 |
20100092428 | Method For Using A Bacillus Subtilis Strain To Enhance Animal Health - The present invention relates to a method for enhancing the health of an animal comprising administering to the animal a composition comprising | 2010-04-15 |
20100092429 | Composition - The present invention provides a composition comprising: (a) one or more live | 2010-04-15 |
20100092430 | ATTENUATED ONCOLYTIC PARAMYXOVIRUSES ENCODING AVIAN CYTOKINES - The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression of the cytokine in the natural host cells leads to a reduced pathogenicity of the virus for avian species. Furthermore the virus genome can encode binding proteins, prodrug-converting enzymes or/and proteases. The selective expression of these molecules in virus-infected tumor cells increases the anti-tumor effect of the virus. | 2010-04-15 |
20100092431 | Edwardsiella Ictaluri Bacteriophage and Uses Thereof - Disclosed are isolated bacteriophage that have lytic activity for species of | 2010-04-15 |
20100092432 | CELL PREPARATION CONTAINING MULTIPOTENTIAL STEM CELLS ORIGINATING IN FAT TISSUE - [Problems] To provide a novel use of multipotential stem cells originating in a fat tissue. | 2010-04-15 |
20100092433 | VASCULARIZED ISLETS AND METHODS OF PRODUCING SAME - An isolated composition of matter is provided comprising a heterogeneous population of cells seeded on a surface of a scaffold, wherein the heterogeneous population of cells comprises at least one pancreatic islet, endothelial cells and fibroblast cells. Methods of generating same and uses thereof are also provided. | 2010-04-15 |
20100092434 | THROMBOPOIETIC ACTIVITY OF TYROSYL-TRNA SYNTHETASE POLYPEPTIDES - Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia. | 2010-04-15 |
20100092435 | USE OF A VARICELLOVIRUS TAP-INHIBITOR FOR THE INDUCTION OF TUMOR-OR VIRUS-SPECIFIC IMMUNITY AGAINST TEIPP - The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity. | 2010-04-15 |
20100092436 | COMPOSITIONS AND METHODS FOR RESTORING IMMUNE RESPONSIVENESS IN PATIENTS WITH IMMUNOLOGICAL DEFECTS - The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the T cells and stimulates at least a portion of the T cells, yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement. Also provided are methods for producing T-cells for the use in diagnostics and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having increased polyclonality produced by these processes are further provided. | 2010-04-15 |
20100092437 | RADIATION INDUCIBLE PROMOTER - The present invention relates to a radiation inducible promoter, more particularly to a radiation inducible promoter including a base sequence represented by SEQ ID NO: 3 derived from | 2010-04-15 |
20100092438 | Bacteria Mediated Gene Silencing - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 2010-04-15 |
20100092439 | ANTIMICROBIALLY-PRIMED MEDICINAL MAGGOT THERAPY - Antimicrobially-primed medicinal maggots and therapy methods are described for the treatment of a variety of indications including, without limitation, infected or non-healing wounds, soft tissue infection and the like (e.g., gangrenous or infected wound). | 2010-04-15 |
20100092440 | COMPOSITION FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE PRINCIPLES IN GYNAECOLOGIC AND RECTAL FIELD AND USES THEREOF - The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all with regard to the viscosity after the dissolution/resuspension of the same in a hydrophilic liquid medium which allows a better adhesion and a direct contact from bacteria to the treated mucosae. Said composition includes a specific viscosizing agent selected from the group of the gums, which can play an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system. | 2010-04-15 |
20100092441 | USE OF NITRITES AND NITRATES AND COMPOSITIONS CONTAINING THESE - Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate. | 2010-04-15 |
20100092442 | BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS - Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a | 2010-04-15 |
20100092443 | NOVEL COMBINATIONS OF NITROGENATED HETEROCYCLIC ANTIBACTERIAL COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THE USE OF SAME AS DRUGS - The invention relates to the combination of nitrogenated heterocyclic antibacterial compounds of formula (I) with other antibacterial compounds and the use of same as drugs. | 2010-04-15 |
20100092444 | PLATELET RICH PLASMA FORMULATIONS FOR CARDIAC TREATMENTS - Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy. | 2010-04-15 |
20100092445 | Adoptive immune cells for tumor vaccines - Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier. | 2010-04-15 |
20100092446 | DRUG SOLUTION HAVING REDUCED DISSOLVED OXYGEN CONTENT, METHOD OF PRODUCING THE SAME AND DRUG SOLUTION CONTAINING UNIT HAVING REDUCED DISSOLVED OXYGEN CONTENT - It is an object of the present invention to provide a drug solution which has a reduced dissolved oxygen content and is less susceptible to oxidative degradation and highly stable over time, a production method therefor, and a drug solution containing pack which is capable of maintaining the dissolved oxygen content of a drug solution at a reduced level, less susceptible to oxidative degradation of the drug solution and highly stable over time. To achieve the aforementioned object, the reduced-dissolved-oxygen-content drug solution is produced by filling and sealing the drug solution in a drug solution container ( | 2010-04-15 |
20100092447 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES - A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | 2010-04-15 |
20100092448 | LOCAL CONTROL OF INFLAMMATION - A medical device includes a carrier and an agent. The agent is formulated to control inflammation of biological tissue, such as heart tissue, and is releasably coupled to the carrier. The carrier is configured to be disposed in operative proximity to the biological tissue to be treated by the agent. In one embodiment, the carrier is configured to release the agent or otherwise deliver the agent to the biological tissue, thus controlling inflammation of the tissue. Also, a method to improve healing of biological tissue includes placing a medical device proximate to the heart of a patient, where the medical device has a carrier and an agent configured to control inflammation, the agent is releasably coupled to the carrier. In one embodiment, the method includes causing the agent to be released from the carrier. | 2010-04-15 |
20100092449 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 2010-04-15 |
20100092450 | Use of Hyaluronidase for the Prevention or Treatment of Arterial Hypertension or Cardiac Insufficiency - The present invention relates to the use of hyaluronidase for the prevention and/or treatment of arterial hypertension or cardiac insufficiency. In addition, the present invention provides a composition and a combined preparation each comprising hyaluronidase and at least one further antihypertensive, and a method of prevention and/or treating arterial hypertension or cardiac insufficiency in a patient in need thereof, wherein the patient is administered a therapeutically effective amount of hyaluronidase. | 2010-04-15 |
20100092451 | Combination Enzyme Therapy for Digestion of Dietary Gluten - A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy. | 2010-04-15 |
20100092452 | Replenishment and Enrichment of Ocular Surface Lubrication - An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents. | 2010-04-15 |
20100092453 | Method of producing porous microparticles - A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile solvent system, and spray drying the system thus formed to provide porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. | 2010-04-15 |
20100092454 | NOVEL USE OF ANTIDEPRESSANT COMPOUNDS AND RELATED COMPOSITIONS - What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin. | 2010-04-15 |
20100092455 | NOVEL ANTI-PROLIFERATION ANTIBODIES - The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. | 2010-04-15 |
20100092456 | METHODS OF TREATMENT - Methods for modulating apoptosis and neurite outgrowth in cells by modulating levels of PtdIns(4,5)P | 2010-04-15 |
20100092457 | Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies - Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed. | 2010-04-15 |
20100092458 | REGULATION OF APG8 PHOSPHORYLATION AND USES THEREOF - The invention relates to proteins and peptides of the alpha isoform of light chain 3 (APG8) and antibodies to the APG8 protein, particularly antibodies that specifically bind to the alpha isoform of APG8 when either phosphorylated or not phosphorylated at serine-12 and antibodies that bind to the gamma isoform of APG8 when either phosphorylated or not phosphorylated at serine-9. The invention also relates to methods of producing these antibodies and use of these antibodies in the treatment of diseases related to autophagocytosis. | 2010-04-15 |
20100092459 | Protein Complex and Uses - The present invention relates to a complex comprising two or more of the proteins S6K2, PKCε and B-Raf. The invention also relates to antibodies that specifically bind to the complex, inhibitors of the complex and uses of the antibodies, inhibitors and complex in diagnosing and preventing chemoresistance in a patient. | 2010-04-15 |
20100092460 | AMINO ACID SEQUENCES DIRECTED AGAINST CHEMOKINES AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2010-04-15 |
20100092461 | Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same - The present invention describes therapeutic agents for chemotherapeutic agent-resistant cancers that include an HLA class I-recognizing antibody as an active ingredient. A further objective of the present invention is to provide methods for treating chemotherapeutic agent-resistant cancers that include the step of administering an HLA class I-recognizing antibody to a subject. It is herein demonstrated that cytotoxic activity due to C3B3 diabody is induced at a lower concentration in chemotherapeutic agent-resistant hematological tumor cell lines having high MDR1 and HLA class IA protein expression, than in their parent cell lines. It was also found that when the chemotherapeutic agent-resistant hematological tumor cell line is pretreated with a C3B3 diabody, cell injury associated with sole use of chemotherapeutic agent is enhanced and the amount of pharmaceutical agents taken up into cells are increased. More specifically, it was discovered that the C3B3 diabody exhibits anti-tumor activity on MDR1-expressing tumor cells having high HLA class I expression, and thereby is effective in overcoming drug resistance. | 2010-04-15 |
20100092462 | Methods for Suppressing Toll-Like Receptor Activity - Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed. | 2010-04-15 |
20100092463 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject - A method is described for treating or preventing a bone loss disease or a bone loss disorder in a mammalian subject or reducing the incidence of a bone loss disease or a bone loss disorder or alleviating the symptoms thereof. The method includes providing to the mammalian subject at least one treatment regimen including at least one follicle-stimulating hormone modulator configured to and in an amount sufficient to reduce bioactivity or bioavailability of follicle-stimulating hormone in the mammalian subject. | 2010-04-15 |
20100092464 | M-CSF-Specific Monoclonal Antibody and Uses Thereof - M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease. | 2010-04-15 |
20100092465 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE - Methods for treating graft-versus-host disease, methods for reducing symptoms of graft-versus-host disease, and methods of reducing the severity of graft-versus-host disease in a patient are disclosed. The methods comprise administering to the patient a therapeutically effective amount of an IL-27 antagonist in combination with a pharmaceutically acceptable vehicle. IL-27 antagonists include soluble IL-27RA proteins and antagonists that comprise an antigen-binding site of an antibody. | 2010-04-15 |
20100092466 | COMBINATION OF ZD6474 AND BEVACIZUMAB FOR CANCER THERAPY - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with bevacizumab; to a pharmaceutical composition comprising ZD6474 and bevacizumab; to a combination product comprising ZD6474 and bevacizumab for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and bevacizumab; to the use of ZD6474 and bevacizumab in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 2010-04-15 |
20100092467 | PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS - Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow. | 2010-04-15 |
20100092468 | METHOD FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO TNF-ALPHA BLOCKING AGENTS - The present invention relates to a method for predicting the responsiveness of a patient to a treatment with a TNF-alpha blocking agent, said method comprising determining the presence or absence of a guanine at position −238, a guanine at position −308, and a cytosine at position −857 of the TNF-alpha gene of said patient, wherein the simultaneous presence of a guanine at position −238, a guanine at position −308, and a cytosine at position −857 of the TNF-alpha gene in both copies of said TNF-alpha gene of said patient is indicative of a lessened likelihood of responsiveness of said patient to a treatment with a TNF-alpha blocking agent with respect to standard responsiveness. | 2010-04-15 |
20100092469 | ANTAGONISTS OF A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS - The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example. | 2010-04-15 |
20100092470 | ANTIBODIES, ANALOGS AND USES THEREOF - Camelid and shark heavy chain only antibodies and their analogs are disclosed. Methods of making such antibodies and their analogs are also provided. Also provided are kits, and methods of using such antibodies and their analogs in diagnostics, prognostics, therapy, and simultaneous diagnosis and therapy. | 2010-04-15 |
20100092471 | Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease - The invention is directed to vaccine compositions and methods based on | 2010-04-15 |
20100092472 | COMPOUNDS AND METHODS FOR THE MODULATION OF BETA-1 INTEGRIN FUNCTION TO MEDIATE TISSUE REPAIR - The present invention provides methods and compositions which modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin. | 2010-04-15 |
20100092473 | ANTI-PHOSPHO-AKT ANTIBODIES - The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 2010-04-15 |
20100092474 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): | 2010-04-15 |
20100092475 | TREATMENT METHOD USING EGFR ANTIBODIES AND SRC INHIBITORS AND RELATED FORMULATIONS - The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described. | 2010-04-15 |
20100092476 | PANCREATIC CANCER BIOMARKERS - The present invention provides a method of diagnosing, prognosing or screening for pancreatic cancer in a subject. The method may be carried out on a sample such as a blood or tissue sample collected from the subject. The is carried out by (a) detecting one or more markers in a biological sample of said subject, said markers selected from the markers set forth in Table 1 (e.g. one or more markers selected from the group set forth in Table 2, and/or the group consisting of ALCAM, TIMP-1, ICAM1, LCN2, REG1A, REG3, IGFBP4, TNFRSF1A and WFDC2); and (b) determining an altered level of said marker(s), said altered level indicating said subject may be afflicted with or at risk of developing pancreatic cancer. Kits useful for carrying out the methods are also described. | 2010-04-15 |
20100092477 | METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER - A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare. | 2010-04-15 |
20100092478 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) - The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases. | 2010-04-15 |
20100092479 | Compositions and methods for treatment of viral diseases - The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). | 2010-04-15 |
20100092480 | MODULATORS OF PROTEIN PHOSPHATASE 2A - Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) core, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A core is also provided. Compositions including mimetics and small molecules of the invention and, optionally, secondary agents may be used to treat disorders in which PP2A activity plays a contributing role. | 2010-04-15 |
20100092481 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2010-04-15 |
20100092482 | Compositions monovalent for CD40L binding and methods of use - The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual. | 2010-04-15 |
20100092483 | Compositions monovalent for CD40L binding and methods of use - The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual. | 2010-04-15 |
20100092484 | CD44 ANTIBODIES - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to CD44, and that function to inhibit CD44. The invention also relates to heavy and light chain immunoglobulins derived from human CD44 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human CD44 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions or medicaments for treatment. | 2010-04-15 |
20100092485 | Genetic Markers for Predicting Responsiveness to Combination Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy. | 2010-04-15 |
20100092486 | MODULATION OF MYELOID DIFFERENTATION PRIMARY RESPONSE GENE 88 (MYD88) EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of MyD88. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating MyD88 expression and for prevention or treatment of diseases wherein modulation of MyD88 expression would be beneficial are provided. | 2010-04-15 |
20100092487 | TOXIC DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in | 2010-04-15 |
20100092488 | Method for Treatment or Prevention of Disease Associated Wtih Functional Disorder of Regulatory T Cell - The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity. | 2010-04-15 |
20100092489 | COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS - The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent. | 2010-04-15 |
20100092490 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR - The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity. | 2010-04-15 |
20100092491 | ANTI-EPCAM ANTIBODY AND USES THEREOF - An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumour selectivity. | 2010-04-15 |
20100092492 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases and disorders characterized by undesirable or excessive endothelial cell proliferation or neovascularization. The monoclonal antibodies and receptors of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF in a test sample. | 2010-04-15 |
20100092493 | Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation - This invention provides, inter alia, methods and compositions for treating, reducing the incidence of, reducing the severity of, or delaying onset or advancement, of synovitis and/or bleeding-associated inflammation in a subject in need thereof. The compositions comprise, and methods make use of, an effective amount of an agent, which abrogates or diminishes activation of the C5aR complement pathway in said subject, and optionally other therapeutic agents including a coagulation factor, other hemostatic factor, and/or second anti-inflammatory agent. | 2010-04-15 |
20100092494 | Composition and method for facilitating the internalization of a therapeutic agent into a cell - The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape. | 2010-04-15 |
20100092495 | POTENT CELL-BINDING AGENT DRUG CONJUGATES - The present invention relates to the use of about 2 to about 8 drug molecules, for example, maytansinoid, per cell binding agent, such as an antibody, and maximal efficacy as compared to a drug load of lesser or higher number of drugs linked to such a cell binding agent. | 2010-04-15 |
20100092496 | CHEMICAL LINKERS AND CONJUGATES THEREOF - The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them. | 2010-04-15 |